About Zembrace® SymTouch®

Sumatriptan is proven efficacious with a well defined safety profile.1

When timing is everything

Whether it’s waking up with a migraine or experiencing rapid-onset pain, patients want relief—fast.1,2


Patients may begin to feel migraine pain relief in as little as 10 minutes (17% of patients vs. 5% for placebo).*


~50% of patients experienced migraine pain relief 30 minutes after administration (47% vs. 15% for placebo).*


A convenient, ready-to-use auto-injector with:

  • A concealed 29 G needle3
  • A discreet, compact design1
  • No refrigeration needed

60% of patients experienced migraine pain relief 2 hours after administration (vs. 21% for placebo).1 Results from a single-attack, parallel group design study, where six different doses of sumatriptan injection, including 3 mg, were compared (n=30 in each group) with placebo (n=62).

Zembrace® SymTouch® offers the lowest dose in a sumatriptan auto-injector.3

Minutes matter

Proportion of patients with migraine pain relief by time with a 3 mg dose of sumatriptan injection (n=30).1 ‡

3 mg dose of sumatriptan
10 mins
30 mins
60 mins
2 hours

Making Migraine Our Priority

Tonix Medicines, Inc. takes pride in providing attentive customer service, having strong industry relationships and being dedicated to uninterrupted supply.

Zembrace® SymTouch® continues our commitment to ensure you have a variety of medication options that can address the unique needs of migraine patients.

Want more information?

Sign up today to learn more about Zembrace® SymTouch®.

    Note: This registration form is intended for healthcare providers only.

    *All fields required.

    Privacy Policy and Authorization

    By clicking the submit button below, you consent to the use by Tonix Medicines, Inc. and its third parties of the information you have provided to periodically send you information about Zembrace® SymTouch® or other products and promotions.

    Tonix Medicines, Inc. and its third parties use the information you provide for legitimate business purposes only and will not sell, share, or otherwise distribute your personal information to third parties. By joining, you acknowledge that your consent to receive automated messages is not required as a condition to purchase goods and services.


    1. Zembrace SymTouch [package insert]. Maple Grove, MN: Upsher-Smith Laboratories, LLC: February 2021.
    2. Mathew NT, et al. Dose ranging efficacy and safety of subcutaneous sumatriptan in the acute treatment of migraine. US Sumatriptan Research Group. Arch Neurol. 1992;49(12):1271-1276
    3. Data on file. Chatham, NJ: Tonix Medicines, Inc.: 2021.